{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shi Z"],"funding":["Science and Technology Project of Tianjin Municipal Health Commission"],"pagination":["e70066"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12423771"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["39(17)"],"pubmed_abstract":["<h4>Background</h4>Advancements in non-small cell lung cancer (NSCLC) therapies have improved outcomes, but challenges like low immune response, drug resistance, and side effects persist. ACT001, a novel small-molecule inhibitor, shows promise in addressing these issues.<h4>Methods</h4>We evaluated ACT001's anti-tumor and immunomodulatory effects in NSCLC. In vitro, its impact on proliferation, migration, invasion, and cell cycle arrest was assessed. In vivo, its effect on tumor growth in C57BL/6 mice was studied. Pull-down assays and mass spectrometry identified ACT001's interaction with STAT1/STAT3 and its regulation of PD-L1 expression.<h4>Results</h4>ACT001 inhibited NSCLC cell proliferation, migration, and invasion, induced cell cycle arrest, and suppressed tumor growth in vivo. It en"],"journal":["Journal of clinical laboratory analysis"],"pubmed_title":["ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non-Small Cell Lung Cancer."],"pmcid":["PMC12423771"],"funding_grant_id":["ZC20178"],"pubmed_authors":["Li Y","Chen Z","Guo H","Shi Z","Hou H","Wang Z","Yu Y","Song Y"],"additional_accession":[]},"is_claimable":false,"name":"ACT001 Inhibits Tumor Progression and Modulates Immune Responses in Non-Small Cell Lung Cancer.","description":"<h4>Background</h4>Advancements in non-small cell lung cancer (NSCLC) therapies have improved outcomes, but challenges like low immune response, drug resistance, and side effects persist. ACT001, a novel small-molecule inhibitor, shows promise in addressing these issues.<h4>Methods</h4>We evaluated ACT001's anti-tumor and immunomodulatory effects in NSCLC. In vitro, its impact on proliferation, migration, invasion, and cell cycle arrest was assessed. In vivo, its effect on tumor growth in C57BL/6 mice was studied. Pull-down assays and mass spectrometry identified ACT001's interaction with STAT1/STAT3 and its regulation of PD-L1 expression.<h4>Results</h4>ACT001 inhibited NSCLC cell proliferation, migration, and invasion, induced cell cycle arrest, and suppressed tumor growth in vivo. It en","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T23:33:04.707Z","creation":"2026-05-24T03:07:08.816Z"},"accession":"S-EPMC12423771","cross_references":{"pubmed":["40836489"],"doi":["10.1002/jcla.70066"]}}